CClinicalTrials.gg
CompletedNCT01647646Updated Jul 24, 2012

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

A Phase 4 interventional study of Seretide in Asthma, sponsored by Far Eastern Memorial Hospital. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-07-24.

Sponsored by Far Eastern Memorial Hospital · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In real life, the investigators will be using different strategies including SMART therapy or other ICS/LABA (medium and high dose) therapy and measure the efficacy for asthma control.

Read the detailed description
  1. All not-well controlled asthma patients would include the study.
  2. We will compare three ways of asthma control including SMART, fixed doses with regular doses and fixed doses with higher doses
  3. We will evaluate the efficacy/safety for these not-well controlled patients.
02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • SMART
  • fixed dose
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 200 is above the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Far Eastern Memorial Hospital is the lead sponsor of 253 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • asthma not well control

Exclusion criteria

Exclusion Criteria:

  • COPD
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Symbicort

    We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period. Intervention drug: Seretide fixed doses therapy

    Drug: Seretide

  • Experimental
    Seretide

    In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year

    Drug: Seretide

Interventions

  • DrugSeretide

    Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety

    Also known as: Symbicort compared with Seretide

06

What researchers measure

Primary outcomes

  1. the percentage of asthma total and well control

    F/U clinical asthma control status and percentage of Acute exacerbation

    Time frame: one year

Secondary outcomes

  1. percentage of asthma acute exacerbation

    Time frame: one year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01647646
Lead sponsor
Far Eastern Memorial Hospital
Responsible party
Shih-Lung Cheng (Chief, Division of Pulmonary Medicine, Far Eastern Memorial Hospital) — Principal investigator
First posted
Jul 23, 2012
Start date
Mar 2009
Primary completion
Feb 2011
Completion
Mar 2012
Last update
Jul 24, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion